Zenas BioPharma: InnoCare reports 7M-share stake

Zenas BioPharma, Inc. (ZBIO) reports that InnoCare Pharma Inc. has filed an initial statement of beneficial ownership as a ten percent owner.

Rhea-AI Filing Summary

Zenas BioPharma, Inc. (ZBIO) reports that InnoCare Pharma Inc. has filed an initial statement of beneficial ownership as a ten percent owner. The filing lists 7,000,000 shares of Common Stock held directly as of August 26, 2026, with no specific acquisition or disposal transaction reported.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider InnoCare Pharma Inc.

Role 10% Owner

Type	Security	Shares	Price	Value
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 7,000,000 shares (Direct)

Key Figures

Common Stock holdings: 7,000,000 shares Ownership status: Ten percent owner Ownership type: Direct ownership

3 metrics

Common Stock holdings 7,000,000 shares Shares of Zenas BioPharma, Inc. Common Stock held following the reported position as of August 26, 2026

Ownership status Ten percent owner InnoCare Pharma Inc. identified as a ten percent owner of Zenas BioPharma, Inc.

Ownership type Direct ownership Reported for the 7,000,000 shares of Common Stock held by InnoCare Pharma Inc.

Key Terms

ten percent owner, Form 3, Common Stock

3 terms

ten percent owner regulatory

"the reporting person is identified as a ten percent owner of Zenas BioPharma, Inc."

Form 3 regulatory

"filed an initial statement of beneficial ownership on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Common Stock financial

"7,000,000 shares of Common Stock held directly"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing disclose about ZBIO ownership?

The Form 3 discloses that InnoCare Pharma Inc. is a ten percent owner of Zenas BioPharma, Inc., reporting 7,000,000 shares of Common Stock held directly as of August 26, 2026.

How many ZBIO shares does InnoCare Pharma Inc. report owning?

InnoCare Pharma Inc. reports ownership of 7,000,000 shares of Zenas BioPharma, Inc. Common Stock, shown as shares held directly following the reported position as of August 26, 2026.

Is the Form 3 for ZBIO reporting a new transaction or just holdings?

The Form 3 for ZBIO reports holdings only. It lists 7,000,000 Zenas BioPharma, Inc. Common Stock shares held directly and does not identify any specific buy or sell transaction, price, or transaction code.

What is InnoCare Pharma Inc.’s status in relation to ZBIO?

InnoCare Pharma Inc. is identified as a ten percent owner of Zenas BioPharma, Inc. in the Form 3, indicating beneficial ownership of 7,000,000 common shares as of August 26, 2026.

Does the ZBIO Form 3 indicate whether the ownership is direct or indirect?

Yes. The Form 3 indicates that the 7,000,000 shares of Zenas BioPharma, Inc. Common Stock reported by InnoCare Pharma Inc. are held with direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 06:51 AM EDT Accepted by SEC EDGAR 09/08/2026 - 06:51 AM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

InnoCare Pharma Inc.

(Last) (First) (Middle)

103 CARNEGIE CENTER, SUITE 209

(Street)

PRINCETON NEW JERSEY 08540

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/26/2026

3. Issuer Name and Ticker or Trading Symbol
Zenas BioPharma, Inc. [ ZBIO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7,000,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Jisong Cui, Chairperson and CEO	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)